# Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

> **NCT06151197** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Endo Pharmaceuticals** · enrollment: 418 (estimated)

## Conditions studied

- Plantar Fibromatosis
- Ledderhose Disease

## Interventions

- **BIOLOGICAL:** EN3835
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06151197
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-28
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 418 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151197, "Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06151197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*